Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Doxorubicin and 24-h paclitaxel plus filgrastim was not superior to doxorubicin and cisplatin in terms of response, PFS or survival in advanced endometrial cancer.

Doxorubicin + Cisplatin vs Doxorubicin + 24-h Paclitaxel + Filgrastim in Endometrial Carcinoma